Illumina (NASDAQ:ILMN) had its price objective increased by SVB Leerink from $420.00 to $430.00 in a report released on Tuesday, Price Targets.com reports. They currently have a market perform rating on the life sciences company’s stock. SVB Leerink also issued estimates for Illumina’s Q4 2021 earnings at $0.62 EPS, FY2021 earnings at $5.77 EPS, FY2021 earnings at $5.54 EPS, Q1 2022 earnings at $0.86 EPS, Q2 2022 earnings at $0.90 EPS, Q3 2022 earnings at $1.11 EPS, Q4 2022 earnings at $1.28 EPS, FY2022 earnings at $4.14 EPS and FY2023 earnings at $5.44 EPS.
ILMN has been the topic of a number of other research reports. Citigroup dropped their target price on shares of Illumina from $450.00 to $400.00 and set a neutral rating on the stock in a research report on Thursday, January 6th. Zacks Investment Research raised shares of Illumina from a strong sell rating to a hold rating and set a $399.00 target price on the stock in a research report on Tuesday, January 4th. Robert W. Baird dropped their target price on shares of Illumina from $493.00 to $437.00 and set a neutral rating on the stock in a research report on Monday, November 8th. TheStreet lowered shares of Illumina from a b- rating to a c rating in a research report on Wednesday, October 6th. Finally, Morgan Stanley initiated coverage on shares of Illumina in a research report on Thursday, January 6th. They set an equal weight rating and a $425.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $443.69.
Shares of Illumina stock opened at $405.14 on Tuesday. The firm has a fifty day simple moving average of $378.55 and a 200-day simple moving average of $428.48. The company has a current ratio of 2.68, a quick ratio of 2.24 and a debt-to-equity ratio of 0.16. Illumina has a 1-year low of $341.03 and a 1-year high of $555.77. The stock has a market capitalization of $63.32 billion, a price-to-earnings ratio of 66.53, a PEG ratio of 3.22 and a beta of 0.90.
In other news, SVP Charles Dadswell sold 314 shares of the company’s stock in a transaction dated Friday, October 22nd. The shares were sold at an average price of $411.00, for a total value of $129,054.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Alexander Aravanis sold 2,926 shares of the company’s stock in a transaction dated Tuesday, October 19th. The stock was sold at an average price of $411.82, for a total transaction of $1,204,985.32. The disclosure for this sale can be found here. Insiders sold a total of 12,189 shares of company stock worth $5,024,576 in the last three months. Insiders own 0.23% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Evermay Wealth Management LLC bought a new stake in shares of Illumina in the 2nd quarter worth about $26,000. Assetmark Inc. acquired a new position in Illumina during the 3rd quarter worth about $26,000. Activest Wealth Management acquired a new position in Illumina during the 2nd quarter worth about $35,000. Logan Capital Management Inc. lifted its position in Illumina by 90.7% during the 3rd quarter. Logan Capital Management Inc. now owns 82 shares of the life sciences company’s stock worth $33,000 after buying an additional 39 shares in the last quarter. Finally, Bell Investment Advisors Inc acquired a new position in Illumina during the 3rd quarter worth about $37,000. 84.89% of the stock is currently owned by institutional investors and hedge funds.
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.
Read More: VIX – Volatility Index
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.